The Technical Analyst
Longeveron Inc. Class A [LGVN]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Longeveron Inc. Class A Price, Forecast, Insider, Ratings, Fundamentals & Signals
-5.25% $1.630
America/New_York / 25 apr 2024 @ 12:11
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 7.82 mill |
| EPS: | -9.65 |
| P/E: | -0.170 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 4.80 mill |
| Avg Daily Volume: | 2.10 mill |
| RATING 2024-04-24 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.170 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -0.170 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.967 (-159.33%) $-2.60 |
| Date: 2024-04-25 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.145 - 2.11 ( +/- 29.71%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Hare Joshua | Buy | 42 553 | Class A Common Stock |
| 2024-04-10 | Hare Joshua | Buy | 106 383 | Class A Common Stock |
| 2024-04-10 | Hare Joshua | Buy | 106 383 | Warrant (right to buy) |
| 2024-04-11 | Hare Joshua | Buy | 42 553 | Warrant (right to buy) |
| 2024-04-11 | Hashad Mohamed Wa'el Ahmed | Buy | 10 638 | Class A Common Stock |
| INSIDER POWER |
|---|
| 39.37 |
| Last 100 transactions |
| Buy: 1 179 927 | Sell: 679 611 |
Forecast:
13:49 - $1.609
Live Trading Signals (every 1 min)
Forecast
1: 12:19 - $1.617
Forecast 2: 13:09 - $1.624
Forecast 3: 13:49 - $1.609
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.630 (-5.25% ) |
| Volume | 0.189 mill |
| Avg. Vol. | 2.10 mill |
| % of Avg. Vol | 8.97 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For LGVN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
LGVN
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
Latest Press Releases
2024-04-18 16:05:00 - Press Release
Longeveron Raises A Total Of $11.4 Million In Gross Proceeds From Warrant Exercise Offering And Public Offering
Miami, april 18, 2024 (globe newswire) -- longeveron inc. (nasdaq: lgvn) (“longeveron” or the “company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (hlhs), alzheimer's disease and aging-related frailty, today announced the closing of its previously announced exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its class a common stock having an exercise price of $2.35 per share, originally issued in october 2023 and april 2024. the issuance or resale of the shares of class a common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on form s-1 (file nos.
2024-04-17 08:00:00 - Press Release
Longeveron Announces Exercise Of Warrants For $6.2 Million Gross Proceeds
Longeveron raises gross proceeds of ~$6.2 m from exercise of certain existing warrants to purchase an aggregate of 2,399,744 shares of its common stock.
2024-04-15 08:30:00 - Press Release
Longeveron's Clear Mind Randomized Phase 2a Clinical Trial Evaluating Lomecel-b™ In Mild Alzheimer's Disease Accepted For Featured Research Session Oral Presentation At The 2024 Alzheimer's Association International Conference (aaic)
Data from longeveron's clear mind phase 2a clinical trial evaluating lomecel-b in alzheimer's disease has been accepted for two presentations at aaic.
2024-04-11 17:17:00 - Press Release
Longeveron Announces Closing Of $5.2 Million Public Offering
Miami, april 11, 2024 (globe newswire) -- longeveron inc. (nasdaq: lgvn) (“longeveron” or the “company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (hlhs), alzheimer's disease and aging-related frailty, today announced the closing of its previously announced public offering of up to 2,234,043 shares of the company's class a common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,234,043 shares of class a common stock at a combined offering price of $2.35 per share (or per pre-funded warrant in lieu thereof) and associated warrant...
2024-04-08 14:15:00 - Press Release
Longeveron Announces Pricing Of $5.25 Million Public Offering
Miami, april 08, 2024 (globe newswire) -- longeveron inc. (nasdaq: lgvn) (“longeveron” or “company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (hlhs), alzheimer's disease and aging-related frailty, today announced the pricing of a public offering of 2,234,043 shares of the company's class a common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 2,234,043 shares of class a common stock at a combined offering price of $2.35 per share (or per pre-funded warrant in lieu thereof) and associated warrant. the warrants will have an exercise price of $2...
Latest News
2024-04-09 06:22:00 - PennyStocks
Future Predictions for Trading Penny Stocks, 3 Changes
The dynamic landscape of investing in penny stocks is poised for notable shifts in the coming year, presenting both seasoned and novice traders with a plethora of opportunities. Key factors contributing to this evolution include technological advancements, regulatory changes, and market sentiment shifts.
2024-02-27 21:56:02 - Seeking Alpha
Longeveron Inc. (LGVN) Q4 2023 Earnings Call Transcript
2024-02-21 16:05:00 - GlobeNewsWire
Longeveron to Report Year-End 2023 Results and Provide Corporate Update February 27, 2024
MIAMI, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, announced today that it will report its 2023 financial results after the market close on February 27, 2024. The Company will host a conference call at 5:00 p.m. ET that day to discuss the Company's results and provide a business update.
2023-11-03 08:00:00 - GlobeNewsWire
Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023
MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its third quarter 2023 financial results prior to the market open on Friday November 10, 2023. The Company will host a conference call and webcast that day to discuss the results, and provide an update on its clinical programs and corporate activities. A question-and-answer session will follow the prepared remarks.
2023-10-05 08:13:00 - Market Watch
Longeveron stock jumps on Alzheimer's trial results
Longeveron Inc. shares LGVN, +4.58% jumped 16% premarket on Thursday after the clinical-stage biotech company announced positive results from a trial of its Alzheimer's treatment Lomecel-B.
2023-09-05 08:00:00 - GlobeNewsWire
Longeveron to Present at the 25th Annual H.C. Wainwright Global Investment Conference
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer's disease and Aging-related Frailty, announced today that the Company's management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13 , 2023 in New York, NY.
2023-08-11 22:16:08 - Seeking Alpha
Longeveron Inc. (LGVN) Q2 2023 Earnings Call Transcript
Longeveron Inc. (NASDAQ:LGVN ) Q2 2023 Earnings Conference Call August 11, 2023 8:00 AM ET Company Participants Mike Moyer - Managing Director, LifeSci Advisors, LLC Wa'el Hashad - Chief Executive Officer Nataliya Agafonova - Chief Medical Officer Lisa Locklear - Chief Financial Officer Joshua Hare - Co-Founder, Chief Science Officer and Chairman Conference Call Participants Michael Okunewitch - Maxim Group Operator Greetings, and welcome to the Longeveron's Second Quarter 2023 Earnings call. At this time, all participants are in a listen-only mode.
2023-08-07 08:00:00 - GlobeNewsWire
Longeveron to Report Second Quarter 2023 Results and Provide Corporate Update on August 11, 2023
MIAMI, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its second quarter 2023 financial results prior to the market open on Friday, August 11, 2023. The Company will host a conference call and webcast that day to discuss the results, provide an update on its clinical programs and corporate activities. A question-and-answer session will follow the prepared remarks.
2023-05-12 14:14:11 - Seeking Alpha
Longeveron Inc. (LGVN) Q1 2023 Earnings Call Transcript
Longeveron Inc. (NASDAQ:LGVN ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants James Clavijo - Chief Financial Officer Wa'el Hashad - Chief Executive Officer Chris Min - Acting Chief Medical Officer & Consultant Conference Call Participants Michael Okunewitch - Maxim Group Operator Good morning, and welcome to Longeveron's call today to discuss the company's 2023 First Quarter and Financial Results. All participants are currently in listen-only mode.
2023-05-12 08:32:08 - InvestorPlace
LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates
Longeveron (NASDAQ: LGVN ) just reported results for the first quarter of 2023. Longeveron reported a loss per share of 22 cents.